{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-006206","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.998334+00:00","generated_at":"2026-06-26T03:11:47.603705+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GlycoMimetics Q1 cash $76.5M; Phase 3 uproleselan OS events trigger now mid-2023; workforce cut 20%","bullets":["Cash and cash equivalents $76.5M at March 31, 2022, down from $90.3M at Dec 31, 2021.","Phase 3 uproleselan trial in relapsed/refractory AML expects OS events trigger mid-2023, top line data shortly after.","IND-enabling studies for GMI-1687 completed; submission on track for H1 2022 in sickle cell disease VOC.","Workforce reduced by 20% in April, mainly early-stage research; executive team added CCO and VP of Tech Ops.","R&D expenses $9.6M (down from $11.1M); G&A $5.1M (up from $4.2M); no revenue recognized."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-006206","json":"https://secwatch.observer/filing/0001558370-22-006206.json","markdown":"https://secwatch.observer/filing/0001558370-22-006206.md","text":"https://secwatch.observer/filing/0001558370-22-006206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022006206/0001558370-22-006206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022006206/glyc-20220428x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:11:47.603705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}